Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) – Research analysts at Jefferies Group reduced their FY2021 EPS estimates for Spectrum Pharmaceuticals in a report issued on Monday. Jefferies Group analyst M. Andrews now anticipates that the biotechnology company will earn $1.07 per share for the year, down from their prior estimate of $1.12. Jefferies Group currently has a “Buy” rating and a $13.00 target price on the stock.

Spectrum Pharmaceuticals (NASDAQ:SPPI) last announced its earnings results on Thursday, August 3rd. The biotechnology company reported ($0.26) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.27) by $0.01. The firm had revenue of $34.30 million during the quarter, compared to analysts’ expectations of $30.50 million. Spectrum Pharmaceuticals had a negative return on equity of 30.95% and a negative net margin of 59.33%. The company’s quarterly revenue was up 1.0% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.35) EPS.

COPYRIGHT VIOLATION WARNING: This story was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this story on another domain, it was stolen and republished in violation of US and international trademark and copyright law. The original version of this story can be accessed at https://www.thecerbatgem.com/2017/09/26/jefferies-group-research-analysts-reduce-earnings-estimates-for-spectrum-pharmaceuticals-inc-sppi.html.

Several other brokerages have also weighed in on SPPI. Zacks Investment Research upgraded Spectrum Pharmaceuticals from a “hold” rating to a “buy” rating and set a $10.00 price objective for the company in a research report on Wednesday, August 9th. HC Wainwright reiterated a “buy” rating and issued a $14.00 price objective on shares of Spectrum Pharmaceuticals in a research report on Thursday, September 14th. ValuEngine upgraded Spectrum Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, August 17th. Finally, BidaskClub lowered Spectrum Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 31st. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $12.00.

Shares of Spectrum Pharmaceuticals (SPPI) traded up 0.762% during midday trading on Tuesday, hitting $9.915. The company had a trading volume of 581,835 shares. The company’s market capitalization is $779.08 million. Spectrum Pharmaceuticals has a 12 month low of $3.21 and a 12 month high of $10.77. The company has a 50-day moving average of $9.43 and a 200-day moving average of $7.42.

A number of institutional investors have recently modified their holdings of SPPI. State of Alaska Department of Revenue grew its position in Spectrum Pharmaceuticals by 77.1% in the second quarter. State of Alaska Department of Revenue now owns 13,918 shares of the biotechnology company’s stock worth $103,000 after acquiring an additional 6,058 shares during the period. Mason Street Advisors LLC grew its position in Spectrum Pharmaceuticals by 8.4% in the first quarter. Mason Street Advisors LLC now owns 16,577 shares of the biotechnology company’s stock worth $108,000 after acquiring an additional 1,279 shares during the period. Piedmont Investment Advisors LLC purchased a new position in Spectrum Pharmaceuticals in the second quarter worth approximately $114,000. Municipal Employees Retirement System of Michigan grew its position in Spectrum Pharmaceuticals by 5.6% in the second quarter. Municipal Employees Retirement System of Michigan now owns 16,720 shares of the biotechnology company’s stock worth $125,000 after acquiring an additional 880 shares during the period. Finally, Pillar Pacific Capital Management LLC purchased a new position in Spectrum Pharmaceuticals in the second quarter worth approximately $138,000. Institutional investors own 66.09% of the company’s stock.

About Spectrum Pharmaceuticals

Spectrum Pharmaceuticals, Inc is a biotechnology company. The Company operates through developing and commercializing oncology and hematology drug products segment. It has a product portfolio consisting of both commercial stage and development stage products that address various cancer types. The Company has six approved oncology/hematology products that target different types of cancer, including non-Hodgkin’s lymphoma (NHL), advanced metastatic colorectal cancer (mCRC), acute lymphoblastic leukemia (ALL) and multiple myeloma (MM).

Earnings History and Estimates for Spectrum Pharmaceuticals (NASDAQ:SPPI)

Receive News & Stock Ratings for Spectrum Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spectrum Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.